Larson Financial Group’s Halozyme HALO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$46.4K Buy
420
+9
+2% +$869 ﹤0.01% 1632
2026
Q2
$32.2K Sell
411
-208
-34% -$14.2K ﹤0.01% 1743
2026
Q1
$40K Buy
619
+345
+126% +$24.3K ﹤0.01% 1465
2025
Q4
$18.4K Sell
274
-80
-23% -$5.38K ﹤0.01% 1768
2025
Q3
$26K Buy
354
+343
+3,118% +$22.8K ﹤0.01% 1489
2025
Q2
$572 Buy
11
+4
+57% +$228 ﹤0.01% 2824
2025
Q1
$447 Buy
7
+5
+250% +$290 ﹤0.01% 2606
2024
Q4
$96 Sell
2
-192
-99% -$9.8K ﹤0.01% 2608
2024
Q3
$11.1K Buy
194
+192
+9,600% +$11K ﹤0.01% 1441
2024
Q2
$105 Hold
2
– – ﹤0.01% 2231
2024
Q1
$81 Hold
2
– – ﹤0.01% 1720
2023
Q4
$74 Buy
+2
New +$75 ﹤0.01% 1732

Other funds holding HALO

Larson Financial Group's HALO Position: Q3 2026 in Review

Larson Financial Group increased its Halozyme (HALO) stake by 2.2% in Q3 2026, buying an estimated $869 and bringing the position to 420 shares worth $46.4K. The position accounts for ﹤0.01% of the portfolio, ranked #1632.

Larson Financial Group first reported a position in HALO in Q4 2023 and has held it in 12 quarters since. 374 funds tracked by Wall St. Rank hold HALO as of Q3 2026.

  • Larson Financial Group held 420 shares of Halozyme worth $46.4K as of Q3 2026.
  • Larson Financial Group bought 9 Halozyme shares in Q3 2026, an estimated $869.
  • Halozyme made up ﹤0.01% of Larson Financial Group's portfolio in Q3 2026, its #1632 holding.
  • Larson Financial Group first reported a position in Halozyme in Q4 2023 and has held it in 12 quarters since.
  • 374 funds tracked by Wall St. Rank held Halozyme as of Q3 2026.

Based on Larson Financial Group's 13F filing for Q3 2026, filed 5 Nov 2026.